Meeting
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
Authors
Nicholas Siu-Li
University of Hawaii John A. Burns School of Medicine, Honolulu, HI
Nicholas Siu-Li , Ian Pagano , Jami Aya Fukui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 549)
DOI
10.1200/JCO.2023.41.16_suppl.549
Abstract #
549
Poster Bd #
379
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Clinical utilization of Breast Cancer Index (BCI) for late recurrence risk assessment and prediction of extended endocrine therapy (EET) benefit in early stage HR+ breast cancer.
First Author: Reshma L. Mahtani
Poster
2023 ASCO Annual Meeting
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.
First Author: Sung Gwe Ahn
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden